From: Evaluation of serum thioredoxin as a hepatocellular carcinoma diagnostic marker
Parameter | HCC group | Cirrhosis group | Control group | P value | Post-hoc analysis |
---|---|---|---|---|---|
Hemoglobin (g/dl) | 10.08 ± 1.51 | 9.97 ± 1.04 | 11.9 ± 0.88 | < 0.001 | P1 = 0.799 |
P2 = 0.002 | |||||
P3 = 0.042 | |||||
White blood cells (109/L) | 6.94 ± 2.72 | 5.73 ± 2.07 | 6.29 ± 0.48 | 0.096 | |
Platelets (109/L) | 102.44 ± 39.97 | 115.33 ± 33.69 | 271.2 ± 22.75 | < 0.001 | P1 = 0.303 |
P2 < 0.001 | |||||
P3 = 0.020 | |||||
Alanine aminotransferase (IU/L) | 76.0 ± 59.36 | 51.73 ± 23.37 | 22.1 ± 3.41 | 0.007 | P1 = 0.140 |
P2 = 0.034 | |||||
P3 = 0.025 | |||||
Aspartate aminotransferase (IU/L) | 79.84 ± 44.96 | 88.6 ± 52.56 | 21.5 ± 3.92 | < 0.001 | P1 = 0.579 |
P2 = 0.042 | |||||
P3 = 0.027 | |||||
Alkaline phosphatase (IU/L) | 231.6 ± 127.36 | 264.73 ± 131.14 | 89.8 ± 17.66 | 0.002 | P1 = 0.436 |
P2 = 0.024 | |||||
P3 = 0.012 | |||||
Gamma Glutamyl transferase (IU/L) | 296.04 ± 159.8 | 79.07 ± 60.29 | 32.8 ± 9.16 | < 0.001 | P1 < 0.001 |
P2 = 0.027 | |||||
P3 = 0.012 | |||||
Total bilirubin (mg/dL) | 2.85 ± 1.86 | 1.94 ± 0.89 | 0.8 ± 0.27 | < 0.001 | P1 = 0.085 |
P2 = 0.032 | |||||
P3 = 0.026 | |||||
Direct bilirubin (mg/dL) | 1.38 ± 1.08 | 0.85 ± 0.58 | 0.16 ± 0.11 | < 0.001 | P1 = 0.087 |
P2 = 0.021 | |||||
P3 = 0.035 | |||||
Serum albumin (g/dL) | 2.78 ± 0.75 | 3.1 ± 0.61 | 4.4 ± 0.64 | < 0.001 | P1 = 0.172 |
P2 < 0.001 | |||||
P3 = 0.053 | |||||
Prothrombin time (sec) | 17.76 ± 5.84 | 17.03 ± 2.99 | 13.9 ± 1.85 | 0.085 | |
Alpha fetoprotein (ng/mL) | 234.32 ± 108.06 | 24.20 ± 10.54 | 6.35 ± 1.24 | < 0.001 | P1 < 0.001 |
P2 < 0.001 | |||||
P3 > 0.050 | |||||
Thioredoxin (ng/mL) | 140.96 ± 12.70 | 88.33 ± 10.34 | 73.10 ± 13.22 | < 0.001 | P1 < 0.001 |
P2 < 0.001 | |||||
P3 < 0.050 |